LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study

Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell–directing activity. Ami combined with carboplatin/pemetrexed (ami-chemo) demonstrated safety and antitumor activity in the phase 1 CHRYSALIS study. PAPILLON (NCT04538664) evaluated ami-chemo vs chemo in first-line EGFR Ex20ins advanced NSCLC.